Respiratory Disorders Treatment Market Navigation, Applications, World Trends & Analysis To 2022-2030

Nation-wide Initiatives Fuel Breakthrough Innovations for Coronavirus and Respiratory Disorders Treatment

As governments across the world grapple with the ongoing COVID-19 (coronavirus), the India Health Fund (IHF) is inviting applications from innovators to address respiratory and airborne infections through its nation-wide search, Quest 2020. Such initiatives are encouraging effective solutions addressing respiratory disorders treatment. Thus, governments in other countries such as the U.S., Italy, and Spain can take cues from such nation-wide initiatives that can help to control COVID-19.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111868

Since coronavirus directly affects the respiratory system of patients, governments, and laboratories have accelerated their research to minimize the severity of the virus among the affected and new patients. Ongoing R&D activities hold promising potential for innovations in the respiratory disorders treatment market. Top-tier companies in India are extending their arms to fund government initiatives in respiratory disorders treatment market. These initiatives are prioritizing the identification and diagnosis of coronavirus. There is a growing need for pre-validated solutions that can be extended for the treatment of coronavirus and other respiratory conditions.

Startups Innovate in Handheld Devices Capable of Delivering Information on Medication Concentrations

There is a growing demand for handheld devices capable of detecting biomarkers and molecules that deploy instant feedback on respiratory disorders. Hence, NOWA Innovations-a University of California, Irvine (UCI) startup, has introduced Unaresp™, a novel device that identifies inhaled medication concentrations and trains patients to correctly inhale medications. Such innovations are anticipated to boost the expansion of the respiratory disorders treatment market, where the market is expected to reach ~US$ 108 Bn by 2027.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies in the respiratory disorders treatment market are increasing their R&D capabilities to develop devices that deliver information about the quality of the patient’s exhalation and the probability of an inflamed airway. Thus, useful information on airway and breath quality is predicted to improve patient outcomes in the respiratory disorders treatment market. Companies in the market for respiratory disorders treatment are increasing efforts to fast-track the device’s approval with the FDA for future commercialization.

Lung Microbiome Deploys Individual Treatment Decisions and Disease Status

The concept of lung microbiome is acquiring popularity in the respiratory disorders treatment market. Since some of the microorganisms in lungs are uninvited gatecrashers, lung microbiome helps to provide information about the status of an individual’s disease status.

Lung microbiome is as unique as an individual’s fingerprint, thus resulting in guided individual treatment decisions that help improve patient quality of life. The novel technique also has the potential to guide companies in the respiratory disorders treatment market to develop new medicines. As such, modern laboratory techniques are being deployed to gain information about the quantity and specificity of bacteria present in the sputum samples of individuals.

View full report@ https://qyresearchmedical.com/report/respiratory-disorders-treatment-market-disease-asthma-chronic-obstructive-pulmonary-disease-copd-lung-cancer-respiratory-tract-infection-allergic-rhinitis-cystic-fibrosis-cf-and-others-drug-class-bronc-019-2030/111868

Several factors such as different organisms moving into the airways as well as environmental factors determine the composition of the lung microbiome among individuals. Thus, the importance of ‘friendly’ gut bacteria is gaining widespread acceptance for respiratory disorders treatment. Healthcare providers in the market of respiratory disorders treatment can increase their efficacy in lung microbiome to identify the symptoms and perhaps decipher the slow progression of respiratory infections.

Demand for Equipment in Low-income Countries to Differentiate Asthma against Self-limiting Viral Infections

Asthma is one of the most common non-communicable disease among children, with a high prevalence worldwide. This is evident since asthma dictates the highest revenue among all diseases in the respiratory disorders treatment market, where the market estimated to progress at a healthy CAGR of ~6% during the forecast period. However, challenges concerning non-availability of equipment and medications for the treatment of asthma in low-resource settings pose as a barrier for market growth. Hence, companies in the respiratory disorders treatment market should increase their production capabilities to meet the demands of healthcare facilities in low-income countries.

Sufficient availability of equipment and necessary medications helps healthcare professionals to differentiate between common respiratory conditions such as pneumonia and asthma versus self-limiting viral infections. Apart from this, there is a growing awareness about non-pharmacological interventions that are underutilized, but can ease symptoms of patients requiring respiratory disorders treatment.

Analysts’ Viewpoint

Given the current public health exigencies amidst the COVID-19 crisis, nation-wide search programs inviting innovators to showcase pre-validated solutions are helping to control the virus. The concept of lung microbiome is acquiring widespread acceptance in the respiratory disorders treatment market to demonstrate how microbiomes are associated with other disorders such as cancer, stroke, and obesity.

Non-pharmacological interventions such as cognitive behavioral techniques are helping to improve the quality of life of chronic obstructive pulmonary disease (COPD) patients. However, there is a need to educate asthma and COPD patients on how to take their medications, which is one of the biggest issues that companies face. Hence, companies should gain expertise in devices that train patients on how to properly inhale their medications.

Respiratory Disorders Treatment Market: Overview

The respiratory disorders treatment market for the historical period 2017–2018 and forecast period 2019–2027, increase in incidence of respiratory disorders, surge in supportive care products to meet the rise in demand for treatment of respiratory disorders, entry of new players, and rise in access to healthcare are projected to drive the global respiratory disorders treatment market

According to the report, the global respiratory disorders treatment market was valued at ~US$ 64 Bn in 2018 and is anticipated to expand at a CAGR of ~6% from 2019 to 2027

Rise in Prevalence of Respiratory Disorders and Surge in Adoption of Combination Therapy: Key Drivers

Rise in focus on smart or digital inhalers for administration of asthma or COPD drugs drives the global respiratory disorders treatment market

Combination therapy includes LAMA-ICS and LABA-ICS. Adoption of combination therapy is increasing, as these are more effective than the separate use of bronchodilator and corticosteroid. Moreover, the number of patients being successfully treated with combination therapy has increased.

Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labor and Welfare (MHLW) have approved the use of combination drugs for the treatment of respiratory disorders such as asthma and COPD

According to the WHO, prevalence of allergic diseases in the developed world has increased significantly in the past 50 years. According to the World Health Organization (White Book on Allergy 2011–2012), allergic rhinitis affects around 30% of the global population.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111868/2900

According to the Global Burden of Disease Study, 251 million COPD cases were reported in 2016 and 3.17 million deaths were caused due to the disease in 2015. Therefore, there is a need of early diagnosis and treatment of the disease.

Focus on Geographic Expansion

Most respiratory disorder-related deaths occur in low- and lower-middle income countries. High prevalence of respiratory diseases, increase in availability of quality health care services, and growth of the pharmaceutical industry in emerging economies across the globe are creating lucrative opportunities in the respiratory disorders treatment market in these countries.

China and Japan are likely to present significant opportunities in the market due to the presence of leading players. In November 2015, F. Hoffmann-La Roche Ltd. opened its new pharmaceutical manufacturing center in Shanghai, China.

Rapid adoption of emerging technologies and surge in innovation are the other important aspects that present opportunities in the respiratory disorders treatment market. Moreover, rapid growth and development of the pharmaceutical industry, rise in availability of branded drugs, and increase of burden of respiratory diseases augment the respiratory disorders treatment market.

Patent Expiry of Branded Products and Availability of Generic Equivalents to Hamper Global Respiratory Disorders Treatment Market

Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by the patent holder. Patent expiry of branded drugs has a significant impact on the pharmaceutical industry. Patent expiry hampers the revenue generated from the sale of branded drugs and can affect the market share of a company.

A few players in the respiratory disorders treatment market face the threat of patient expiry, which increases the availability of generic versions of drugs and create pricing pressure on the manufacturers

For instance, AstraZeneca’s Symbicort Turbuhaler went off patent in Europe in 2019, while patents of GlaxoSmithKline plc’s Qvar, Singulair, and Diskus have expired. This is likely to lead to dramatic losses in sales, thereby affecting positions of the companies in the global respiratory disorders treatment market.

Respiratory Disorders Treatment Market: Competition Landscape

This report profiles major players in the global respiratory disorders treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global respiratory disorders treatment market is less fragmented, with the presence of large number of international as well as regional players

Leading players operating in the global respiratory disorders treatment market are 

  • Mylan N.V
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries
  • CHIESI Farmaceutici S.p.A.
  • Cipla
  • Vertex Pharmaceuticals Incorporated.

Key Questions Answered in Respiratory Disorders Treatment Market Report

  • What is the scope of growth of combination drugs in the global respiratory disorders treatment market?
  • What will be the Y-o-Y growth of the global respiratory disorders treatment market between 2019 and 2027?
  • What is the influence of changing trends in target therapies on the global respiratory disorders treatment market?
  • Will North America continue to be the most profitable regional market for respiratory disorders treatment providers?
  • Which factors are anticipated to hamper the growth of the global respiratory disorders treatment market during the forecast period?
  • Which are the leading companies in the global respiratory disorders treatment market?

Respiratory Disorders Treatment Market – Segmentation

Disease

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Cancer
  • Respiratory Tract Infection
  • Allergic Rhinitis
  • Cystic Fibrosis (CF)
  • Others

Drug Class

  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Antibiotics
  • Target Therapy
  • Immunotherapy
  • CFTR
  • Others

Route of Administration

  • Oral
  • Nasal
  • Injectable

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Disorders Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Route of Administration Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Respiratory Disorders Treatment Market Analysis and Forecast, 2017–2030

4.4.1. Market Revenue Projections (US$ Bn)

4.5. Porter’s Five Force Analysis

5. Key Insights

5.1. Health Care Industry Overview

5.2. Health Care Industry Overview

5.3. Pipeline Analysis (asthma, lung cancer, COPD)

5.4. Disease Prevalence Rate in Key Countries

5.5. Disease Management

5.6. Key Market Events

5.7. Regulatory Scenario

5.8. Reimbursement Scenario

5.9. Technological Advancements

6. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.1.1. Key Findings / Developments

6.2. Global Respiratory Disorders Treatment Market Value Forecast, by Drug Class, 2017–2030

6.2.1. Bronchodilators

6.2.2. Corticosteroids

6.2.3. Combination Drugs

6.2.4. Antibiotics

6.2.5. Target Therapy

6.2.6. Immunotherapy

6.2.7. CFTR

6.3. Others Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class

7. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Disease

7.1. Introduction & Definition

7.1.1. Key Findings / Developments

7.2. Global Respiratory Disorders Treatment Market Value Forecast, by Disease, 2017–2030

7.2.1. Asthma

7.2.2. Chronic Obstructive Pulmonary Disease (COPD)

7.2.3. Lung Cancer

7.2.4. Respiratory Tract Infection

7.2.5. Allergic Rhinitis

7.2.6. Cystic Fibrosis (CF)

7.2.7. Others

7.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease

8. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Route of Administration 

8.1. Introduction & Definition

8.1.1. Key Findings / Developments

8.2. Global Respiratory Disorders Treatment Market Value Forecast, by Route of Administration, 2017–2030

8.2.1. Oral

8.2.2. Nasal

8.2.3. Injectable

8.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration

9. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Distribution Channel 

9.1. Introduction & Definition

9.1.1. Key Findings / Developments

9.2. Global Respiratory Disorders Treatment Market Value Forecast, by Distribution Channel, 2017–2030

9.2.1. Hospital Pharmacies

9.2.2. Retail Pharmacies

9.2.3. Online Pharmacies

9.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel

10. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Region

…….

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111868/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi